Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine adds to its board of directors

Jessica Hopfield will also serve on the genome editing firm's audit committee

Jessica HopfieldGenome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who will also serve on the board's audit committee.

She said: “I am honoured to join Editas Medicine’s board of directors.

Editas is on the forefront of a new era in medicine, and I look forward to working with the team and helping guide the company in the coming years.”

Dr Hopfield has more than two decades worth of experience in the medical and healthcare fields and she has held management positions at Merck Sharp & Dohme (MSD) in clinical development, outcomes research and marketing.

Katrine Bosley, president and chief executive officer of Editas Medicine, said: “With her wide range of scientific and business expertise, Jessica brings great strategic acumen to Editas Medicine, and I am pleased to welcome her to our board of directors.

“Her contributions as a director on our board will be vital as work towards achieving our long-range goals for the year 2022 and vision for advancing Editas Medicine as a leading genome editing company.”

22nd February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics